The National Blood Authority (NBA) released information today about the arrangements to add emicizumab (Hemlibra®) as a treatment for Australians along with the other treatments for bleeding disorders on the National Product List.
Adding Hemlibra to the National Product List means that there will be consistent access to the treatment around Australia. The National Blood Authority said, ‘Hemlibra will be prescribed by a specialist clinician in a recognised Haemophilia Treatment Centre, which will continue to provide coordinated access consistent with the current framework for access to therapies for haemophilia. Supply of Hemlibra under NBA arrangements is expected to commence by December 2020.’
More information about access and transition arrangements is available on the National Blood Authority website – National supply arrangements for Hemlibra
Emicizumab is a treatment that can reduce or stop bleeding in people with severe or moderate haemophiia A with and without inhibitors.